News & Updates
Filter by Specialty:
Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.
Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE
11 Sep 2024
COVID-19 infection ups CV risk in people living with HIV
People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.
COVID-19 infection ups CV risk in people living with HIV
26 Aug 2024
![[PD Test]Is exposure to antenatal corticosteroid harmful in the long run?](https://sitmspst.blob.core.windows.net/images/articles/is-exposure-to-antenatal-corticosteroid-harmful-in-the-long-run-9fd2626e-f317-43d9-b6a8-7ed550fef073-square.jpg)
[PD Test]Is exposure to antenatal corticosteroid harmful in the long run?
Antenatal exposure to corticosteroids, particularly betamethasone, does not increase the prevalence of cardiovascular risk factors or the incidence of major adverse cardiovascular events (MACE) up to 50 years of age, suggests a study.
[PD Test]Is exposure to antenatal corticosteroid harmful in the long run?
14 Aug 2024
Expectant mums’ use of dolutegravir safe for babies
Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.
